🇺🇸 FDA
Pipeline program

Pioglitazone

AD-4833/TOMM40_301

Phase 3 small_molecule terminated

Quick answer

Pioglitazone for Mild Cognitive Impairment Due to Alzheimer's Disease is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 2 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Mild Cognitive Impairment Due to Alzheimer's Disease
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials